Letter to the Editor | Published:

CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes

Leukemia volume 31, pages 22542257 (2017) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I anigens. JCI 2017; 127: 2705–2718.

  2. 2.

    , , , , , et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013; 5: 176ra33.

  3. 3.

    , , , , , et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin Cancer Res 2014; 20: 4036–4046.

  4. 4.

    , , , , , et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood 2014; 123: 3296–3304.

  5. 5.

    , , , , , et al. TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms. J Immunol 2011; 186: 3265–3276.

  6. 6.

    , , , , , et al. TTI-621 (SIRPalphaFc): a CD47-blocking innate immune checkpoint inhibitor with broad anti-tumor activity and minimal erythrocyte binding. Clin Cancer Res 2016; 23: 1068–1079.

  7. 7.

    , . Loss of CD47 makes dendritic cells see red. Immunity 2015; 43: 622–624.

  8. 8.

    , , , , , et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013; 341: 88–91.

  9. 9.

    , , . Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 2016; 16: 131–144.

  10. 10.

    , , , , , et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 2015; 21: 1209–1215.

  11. 11.

    , , , , , et al. Signal regulatory protein (SIRPalpha), a cellular ligand for CD47, regulates neutrophil transmigration. J Biol Chem 2002; 277: 10028–10036.

  12. 12.

    . Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119: 5640–5649.

  13. 13.

    , , , , , et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477–6489.

  14. 14.

    , , , , , et al. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology 2009; 126: 386–393.

  15. 15.

    , , , , , et al. Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rgammaKO mice. J Immunol 2012; 188: 6145–6155.

Download references

Acknowledgements

Author contributions

MDM—experimental design, animal experiments, drafting of manuscript; JTS—experimental design, in vitro experiments, drafting of manuscript; AYC—Pr20 characterization, biochemistry and immunology, drafting of manuscript; KST—statistical design and analysis; CL—creation and manufacturing of ESK and Pr20; KCG—experimental design, analysis, drafting of manuscript; DAS—experimental design, analysis, drafting of manuscript.

Author information

Author notes

    • M D Mathias
    • , J T Sockolosky
    • , K C Garcia
    •  & D A Scheinberg

    These authors contributed equally to this work.

Affiliations

  1. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • M D Mathias
  2. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • M D Mathias
    • , A Y Chang
    •  & D A Scheinberg
  3. Weill Cornell Medicine, New York, NY, USA

    • M D Mathias
    • , A Y Chang
    •  & D A Scheinberg
  4. Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA, USA

    • J T Sockolosky
    •  & K C Garcia
  5. Department of Statistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • K S Tan
  6. Eureka Therapeutics, Emeryville, CA, USA

    • C Liu

Authors

  1. Search for M D Mathias in:

  2. Search for J T Sockolosky in:

  3. Search for A Y Chang in:

  4. Search for K S Tan in:

  5. Search for C Liu in:

  6. Search for K C Garcia in:

  7. Search for D A Scheinberg in:

Competing interests

CL: equity in Eureka; KCG: equity in Alexo Therapeutics; DAS: consultant to Eureka. The remaining authors declare no conflict of interest.

Corresponding authors

Correspondence to K C Garcia or D A Scheinberg.

Supplementary information

About this article

Publication history

Published

DOI

https://doi.org/10.1038/leu.2017.223

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)